yingweiwo

CDK

CDK

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle.Additionally, they control mRNA processing, transcription, and nerve cell differentiation. With molecular weights between 34 and 40 kDa, CDKs are relatively small proteins that only contain the kinase domain. In fact, when their CDK gene has been replaced with the homologous human gene, yeast cells can proliferate normally. A CDK by definition binds the control protein cyclin. Only the cyclin-CDK complex is an active kinase; CDK lacks much kinase activity on its own.

Around 20 Cyclin-dependent kinases (CDK1-20) have been identified as of yet. While CDK 7, 8, 9 and 11 are linked to transcription, CDK1, 4, and 5 are involved in the cell cycle.

The majority of CDK regulation occurs post-translationally, and CDK levels are essentially constant throughout the cell cycle. The majority of knowledge about CDK structure and function is based on CDKs from vertebrates (CDC2 and CDK2), S. pombe (CDC28), and S. cerevisiae (Cdc2). Cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and CDK inhibitory subunit (CKI) binding are the four main mechanisms of CDK regulation.

CDK related products

Structure Cat No. Product Name CAS No. Product Description
CDKI-73 V8118 CDKI-73 1421693-22-2 CDKI-73 is a novel and potent CDK9 inhibitor with Ki of 4 nM.
Cimpuciclib V52250 Cimpuciclib 2202767-78-8 Cimpuciclib is a selective CDK4 inhibitor (IC50= 0.49 nM) with anti-tumor activity.
Cirtuvivint (SM08502) V52248 Cirtuvivint (SM08502) 2143917-62-6 Cirtuvivint (SM08502) is a potent orally bioactive CDC-like kinase (CLK) inhibitor for solid tumor research.
CK7 V52984 CK7 507487-89-0 CK7, a Cdk2/9 inhibitor, may be utilized to prepare the Nek1 inhibitors BSc5231 and BSc5367.
CKI-7 2HCl V5054 CKI-7 2HCl 1177141-67-1 CKI-7 2HCl is a novel, potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM.
CLK-IN-T3 V4769 CLK-IN-T3 2109805-56-1 CLK-IN-T3 is a novel, potent and highly selective CLK (CDC-like kinase)inhibitor with high specificity to CLK1-3 protein isoforms and with IC50s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively.
CLK-IN-T3N V75981 CLK-IN-T3N 2561494-73-1 CLK-IN-T3N is the negative control (NC) of CLK-IN-T3, a probe for CLK.
CLK1-IN-2 V77146 CLK1-IN-2 3029431-68-0 CLK1-IN-2 is a metabolically stable Clk1 inhibitor.
CLK1-IN-3 V52240 CLK1-IN-3 2922550-28-3 CLK1-IN-3 (compound 10ad) is a potent and specific Clk1 inhibitor (antagonist) with IC50 of 5 nM and is over 300-fold selective over Dyrk1A.
CLZX-205 V92091 CLZX-205 3033694-01-5 CLZX-205 (compound C-7) is a selective inhibitor of CDK9 with IC50 of 2.9 nM.
CPS2 V52224 CPS2 2756741-90-7 CPS2 is a highly efficient, selective, irreversible PROTAC CDK2 degrader (IC50= 24 nM).
Crozbaciclib fumarate V52217 Crozbaciclib fumarate 2567494-39-5 Crozbaciclib fumarate is an inhibitor (blocker/antagonist) of CDK4/6 with IC50s of 3 and 1 nM respectively.
CVT-313 V18895 CVT-313 199986-75-9 CVT-313 (Cdk2 Inhibitor III) is a potent ATP-competitive and selective CDK2 inhibitor (antagonist) with IC50 of 0.5 μM.
Cyclin K degrader 1 V84503 Cyclin K degrader 1
Dalpiciclib hydrochloride (SHR-6390 hydrochloride) V52200 Dalpiciclib hydrochloride (SHR-6390 hydrochloride) 2891598-76-6 Dalpiciclib (SHR-6390) HCl is an orally bioactive and selective CDK4/6 inhibitor (antagonist) with IC50s of 12.4 nM and 9.9 nM, respectively.
DB18 V84683 DB18 2587177-94-2
DD-03-156 ((S,R,S)-AHPC-Me-PEG2-dabrafenib) V53108 DD-03-156 ((S,R,S)-AHPC-Me-PEG2-dabrafenib) 2769753-69-5 DD-03-156 is a potent and specific degrader of CDK17 and LIMK2.
DS96432529 V52936 DS96432529 2871872-79-4 DS96432529 is a potent bone anabolic agent with orally bioactive and CDK8 inhibitory activity.
Ebvaciclib (PF-06873600) V4452 Ebvaciclib (PF-06873600) 2185857-97-8 Ebvaciclib (PF-06873600; PF06873600) is a novel, potent, selective and orally bioavailable pan-inhibitor of cyclin-dependent kinase (CDK) with potential antitumor activity.
Eciruciclib V53301 Eciruciclib 1868086-40-1 Eciruciclib is an anticancer agent and a potent cyclin-dependent kinase (CDK) inhibitor.
Contact Us